{"entity":{"id":"nct05582850","kind":"trial","name":"DT-9081 Study in Participants With Advanced, Recurrent or Metastatic Solid Tumours","aka":[],"tldr":"A phase 1 trial of DT-9081 run by Domain Therapeutics SA, terminated.","summary":"DT-9081 Study in Participants With Advanced, Recurrent or Metastatic Solid Tumours is a phase 1 interventional study registered as NCT05582850 by Domain Therapeutics SA, with 29 participants enrolled, started 2022-11-24. Conditions recorded: Solid Tumor, Adult. Interventions recorded: DT-9081 - dose escalation and DT-9081 - expansion.","status":"historic","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT05582850","url":"https://clinicaltrials.gov/study/NCT05582850"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["dt-9081"],"companies":["domain-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05582850","phase":"1","setting":"A Phase 1, Multicentre, Open-label, Dose-escalation and Expansion Study to Determine a Recommended Phase 2 Dose (RP2D) of DT-9081 in Participants With Advanced Solid Tumours","sponsor":"Domain Therapeutics SA","enrolled":29,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05582850/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"dt-9081","kind":"drug","name":"DT-9081","route":"/drugs/dt-9081/"}],"company":[{"id":"domain-therapeutics","kind":"company","name":"Kainova Therapeutics","route":"/companies/domain-therapeutics/"}]}}